Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein(a)

Atherosclerosis Supplements

Volumn 10, Issue 5, 2009, Pages 85-88

  Kassner, U ^a   Vogt, A ^b   Rosada, A ^a   Barz, F ^a   Giannakidou Jordan, E ^a   Berthold, H K ^a   Steinhagen Thiessen, E ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cardiovascular disease; Lipid apheresis; Lp(a)

Indexed keywords

LIPOPROTEIN A;

APHERESIS; ARTICLE; CARDIOVASCULAR RISK; CLINICAL EFFECTIVENESS; CORONARY ARTERY DISEASE; GERMANY; HUMAN; HYPERLIPOPROTEINEMIA; LIPOPROTEIN BLOOD LEVEL; METHODOLOGY; OBSERVATIONAL METHOD; PRIORITY JOURNAL; RANDOMIZATION;

BIOLOGICAL MARKERS; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; EVIDENCE-BASED MEDICINE; GERMANY; HUMANS; HYPERLIPIDEMIAS; LIPOPROTEIN(A); PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; TREATMENT OUTCOME; UP-REGULATION;

EID: 72649086379     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5688(09)71818-5     Document Type: Article

References (25)

1. Berg K. A new serum type system in man: the Lp system. Acta Pathol Microbiol Scand 59 (1963) 362-382
2. Marcovina S.M., and Koschinsky M.L. Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 82 12A (1998) 57U-66U
3. Hobbs H.H., and White A.L. Lipoprotein(a): intrigues and insights. Curr Opin Lipidol 10 3 (1999) 225-236
4. Boerwinkle E., Leffert C.C., Jingping L., Lackner C., Chiesa G., and Hobbs H.H. Apolipoprotein(a) accounts for greater than 90% of the variation in plasma lipoprotein (a) concentrations. J Clin Invest 90 (1992) 52-60
5. Gaw A., Brown E.A., and Ford I. Impact of apo(a) length polymorphism and the control of plasma Lp(a) concentrations: evidence for a threshold effect. Arterioscler Thromb Vasc Biol 18 12 (1998 Dec) 1870-1876
6. Nielsen L.B., Gronholdt M.L.M., Schroeder T.V., Stender S., and Nordestgaard B.G. In vivo transfer of lipoprotein (a) into human athersclerotic carotid arterial intima. Arterioscler Thromb Vasc Biol 17 5 (1997) 905-911
7. Rath M., Niendorf A., Reblin T., Dietel M., Krebber H.J., and Beisiegel U. Detection and quantification of lipoprotein(a) in the arterial wall of 107 coronary bypass patients. Eur Heart J 11 Suppl E (1990 Aug) 174-183
8. Boffa M.B., Marcovina S.M., and Koschinsky M.L. Lipoprotein(a) as a risk factor for atherosclerosis and thrombosis: mechanistic insights from animal models. Clin Biochem 37 5 (2004) 333-343.8
9. Poon M., Zhang X., Dunsky K.G., Taubman M.B., and Harpel P.C. Apolipoprotein(a) induces monocyte chemotactic activity in human vascular endothelial cells. Circulation 96 8 (1997) 2514-2519
10. Cremer P., Nagel D., Labrot B., Mann H., Müller-Berninger R., Elster H., and Seidel D. Ten-year follow-up results from the Goettingen risk, incidence and prevalence study (GRIPS). I. Risk factors for myocardial infarction in a cohort of 5790 men. Atherosclerosis 129 (1997) 221-230
11. Bostom A.G., Cupples L.A., Jenner J.L., Ordovas J.M., Seman L.J., Wilson P.W., Schaefer E.J., and Castelli W.P. Elevated plasma lipoprotein(a) and coronary heart disease in men aged 55 years and younger. A prospective study. JAMA 276 (1996) 544-548
12. Craig W.Y., Neveux L.M., Palomaki G.E., Cleveland M.M., and Haddow J.E. Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies. Clin Chem. 44 11 (1998 Nov) 2301-2306
13. Danesh J., Collins R., and Peto R. Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 102 10 (2000 Sep 5) 1082-1085
14. Bennet A., Di Angelantonio E., Erqou S., Eiriksdottir G., Sigurdsson G., Woodward M., Rumley A., Lowe G.D., Danesh J., and Gudnason V. Lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data. Arch Intern Med 168 6 (2008 Mar 24) 598-608
15. Kamstrup P.R., Benn M., Tybjaerg-Hansen A., and Nordestgaard B.G. Extreme lipoprotein(a) levels and risk of myocardial infarction in the general population: the Copenhagen City Heart Study. Circulation 117 2 (2008 Jan 15) 176-184
16. Emerging Risk Factors Collaboration, Erqou S., Kaptoge S., Perry P.L., Di Angelantonio E., Thompson A., White I.R., Marcovina S.M., Collins R., Thompson S.G., and Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302 4 (2009 Jul 22) 412-423
17. Carlson, Hamsten, Asplund, Carlson L.A., Hamsten A., Asplund A., et al. Pronounced lowering of serum lipoprotein Lp(a) in hyperlipemic subjects treated with nicotinic acid. J Intern Med 226 (1989) 271
18. Goldberg A., Alagona Jr. P., Capuzzi D.M., Guyton J., Morgan J.M., Rodgers J., Sachson R., and Samuel P. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85 9 (2000 May 1) 1100-1105
19. Merki E., Graham M.J., Mullick A.E., Miller E.R., Crooke R.M., Pitas R.E., Witztum J.L., and Sotirios Tsimikas S. Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice. Circulation 118 (2008) 743-753
20. Jaeger B.R., Richter Y., Nagel D., Heigl F., Vogt A., Roeseler E., Parhofer K., Ramlow W., Koch M., Utermann G., Labarrere C.A., Seidel D., and Group of Clinical Investigators. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6 3 (2009 Mar) 229-239
21. Keller C. Apheresis in coronary heart disease with elevated Lp (a): a review of Lp (a) as a risk factor and its management. Ther Apher Dial 11 1 (2007 Feb) 2-8
22. Thompson G.R., HEART-UK L.D.L., and Apheresis Working Group. Recommendations for the use of LDL apheresis. Atherosclerosis 198 2 (2008 Jun) 247-255
23. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., Stone N.J., and Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 3 (2004 Aug 4) 720-732 Review.
24. Graham I., Atar D., Borch-Johnsen K., Boysen G., Burell G., Cifkova R., Dallongeville J., De Backer G., Ebrahim S., Gjelsvik B., Herrmann- Lingen C., Hoes A., Humphries S., Knapton M., Perk J., Priori S.G., Pyorala K., Reiner Z., Ruilope L., Sans-Menendez S., Op Reimer W.S., Weissberg P., Wood D., Yarnell J., Zamorano J.L., and ESC Committee for Practice Guidelines. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Atherosclerosis 194 1 (2007 Sep) 1-45
25. G-BA, Blutreinigungsverfahren zur Behandlung einer selten auftretenden Fettstoffwechselstörung wird GKV-Leistung. Homepage G-BA 2008 Jun 20.